• Please log in or register to access this feature.

Cancer Cell Biology

You have full text access to this OnlineOpen article

Expression of CD147 is associated with prostate cancer progression

  1. Wei-de Zhong1,2,†,
  2. Yu-xiang Liang3,†,
  3. Sharron X. Lin4,†,
  4. Ling Li5,
  5. Hui-chan He1,
  6. Xue-cheng Bi1,
  7. Zhao-dong Han1,
  8. Qi-shan Dai1,
  9. Yong-kang Ye1,
  10. Qing-biao Chen1,
  11. Yue-sheng Wang1,
  12. Guo-hua Zeng2,6,
  13. Gang Zhu7,
  14. Zheng Zhang1,
  15. Zhi-nan Chen8,
  16. Chin-Lee Wu4,‡,*

Article first published online: 27 APR 2011

DOI: 10.1002/ijc.25982

Issue

International Journal of Cancer

International Journal of Cancer

Volume 130, Issue 2, pages 300–308, 15 January 2012

Additional Information

How to Cite

Zhong, W.-d., Liang, Y.-x., Lin, S. X., Li, L., He, H.-c., Bi, X.-c., Han, Z.-d., Dai, Q.-s., Ye, Y.-k., Chen, Q.-b., Wang, Y.-s., Zeng, G.-h., Zhu, G., Zhang, Z., Chen, Z.-n. and Wu, C.-L. (2012), Expression of CD147 is associated with prostate cancer progression. Int. J. Cancer, 130: 300–308. doi: 10.1002/ijc.25982

Author Information

  1. 1

    Department of Urology, Guangzhou First Municipal People's Hospital, Guangzhou Medical College, Guangzhou, China

  2. 2

    Guangdong Key Laboratory of Urology, Guangzhou, China

  3. 3

    Graduate School of Southern Medical University, Guangzhou, China

  4. 4

    Departments of Pathology and Urology, Massachusetts General Hospital and Harvard Medical School, Boston, MA

  5. 5

    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

  6. 6

    Department of Urology, First Affiliated Hospital of Guangzhou Medical College, Guangzhou, China

  7. 7

    Department of Urology, Beijing Hospital of Ministry of Public Health, Beijing, China

  8. 8

    Department of Cell Biology and Cell Engineering Research Centre, the Fourth Military Medical University, Xian, China

  1. †

    W.Z., Y.L., and S.X.L contributed equally to this work.

  2. ‡

    Tel : 617-726-8454, Fax: +1-617-724-7803

*Departments of Pathology and Urology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA

  • †

    W.Z., Y.L., and S.X.L contributed equally to this work.

  • ‡

    Tel : 617-726-8454, Fax: +1-617-724-7803

Publication History

  1. Issue published online: 23 NOV 2011
  2. Article first published online: 27 APR 2011
  3. Accepted manuscript online: 15 FEB 2011 01:16PM EST
  4. Manuscript Accepted: 5 JAN 2011
  5. Manuscript Received: 2 AUG 2010

Funded by

  • Natural Science Foundation of Guangdong Province. Grant Number: 04003650
  • Key Programs of Health Bureau of Guangzhou city. Grant Number: 2007-Zdi-05
  • National High Technology Research and Development Project of China. Grant Numbers: 2006AA02A245, 2007AA022001
  • National Natural Science Foundation of China. Grant Number: 30872960
  • Guangdong Province (Provincial Key Research Laboratory on Prostate Disease)
  • John and Claire Bertucci Prostate Cancer Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (519K)

References

  • 1
    Kakehi Y. Watchful waiting as a treatment option for localized prostate cancer in the PSA era. Jpn J Clin Oncol 2003; 33: 1–5.
  • 2
    Rubin MA. Targeted therapy of cancer: new roles for pathologists—prostate cancer. Mod Pathol 2008; 21( Suppl. 2): S44–55.
  • 3
    Graham J, Baker M, Macbeth F, Titshall V; Guideline Development Group. Diagnosis and treatment of prostate cancer: summary of NICE guidance. BMJ 2008; 336: 610–2.
  • 4
    Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Møller H, Reuter V, Fearn P, Eastham J, Scardino P. Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 2006; 95: 1186–94.
  • 5
    Kattan MW, Cuzick J, Fisher G, Berney DM, Oliver T, Foster CS, Møller H, Reuter V, Fearn P, Eastham J, Scardino PT. Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer 2008; 112: 69–74.
    Direct Link:
  • 6
    Gabison EE, Mourah S, Steinfels E. Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas. Am J Pathol 2005; 166: 209–219.
  • 7
    Tang Y, Kesavan P, Nakada MT, Yan L. Tumor–stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res 2004; 2: 73–80.
  • 8
    Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P Bugelski P, Yan L. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 2005; 65: 3193–9.
  • 9
    Marieb EA, Zoltan-Jones A, Li R, Misra S, Ghatak S, Cao J, Zucker S, Toole BP. Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res 2004; 64: 1229–32.
  • 10
    Yang JM, O'Neill P, Jin W, Foty R, Medina DJ, Xu Z, Lomas M, Arndt GM, Tang Y, Nakada M, Yan L, Hait WN. Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to anoikis through inhibition of Bim. J Biol Chem 2006; 281: 9719–27.
  • 11
    Vignesw N, Beckers S, Waigel S, Mensah J, Wu J, Mo J, Fleisher KE, Bouquot J, Sacks PG, Zacharias W. Increased EMMPRIN (CD 147) expression during oral carcinogenesis. Exp Mol Pathol 2006; 80: 147–59.
  • 12
    Ranuncolo SM, Armanasco E, Cresta C. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 2003; 106: 745–51.
    Direct Link:
  • 13
    Sienel W, Hellers J, Morresi-Hauf A. Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 2003; 103: 647–651.
    Direct Link:
  • 14
    Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002; 99: 157–166.
    Direct Link:
  • 15
    Zou W, Yang H, Hou X, Zhang W, Chen B, Xin X. Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to paclitaxel in HO-8910pm cells. Cancer Lett 2007; 248: 211–8.
  • 16
    Epstein JI, Allsbrook WC, Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228–42.
  • 17
    Han ZD, Bi XC, Qin WJ, He HC, Dai QS, Zou J, Ye YK, Liang YX, Zeng GH, Chen ZN, Zhong WD. CD147 Expression indicates unfavourable prognosis in prostate Cancer. Pathol Oncol Res 2009; 15: 369–74.
  • 18
    Han ZD, Bi XC, Qin WJ, He HC, Dai QS, Zou J, Ye YK, Liang YX, Zeng GH, Chen ZN, Zhong WD. Expression and clinical significance of CD147 in genitourinary carcinomas. J Surgical Res 2010; 160: 260–7.
  • 19
    Liang YX, He HC, Han ZD, Bi XC, Dai QS, Ye YK, Qin WJ, Zeng GH, Zhu G, Xu CL, Zhong WD. CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value. Cancer Invest 2009; 27: 788–93.
  • 20
    Li Y, Shang P, Qian AR. Inhibitory effects of antisense RNA of HAb18G/CD147 on invasion of hepatocellular carcinoma cells in vitro. World J Gastroenterol 2003; 9: 2174–7.
  • 21
    Sun JX, Martin E, Hemle ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 2001; 61: 2276–81.
  • 22
    Sidhu SS, Mengistab AT, Tauscher AN, LaVail J, Basbaum C. The microvesicle as a vehicle for EMMPRIN in tumor–stromal interactions. Oncogene 2004; 23: 956–63.
  • 23
    Nabeshima K, Suzumiya J, Nagano M, Ohshima K, Toole BP, Tamura K, Iwasaki H, Kikuchi M. Emmprin, a cell surface inducer of matrix metalloproteinases (MMPs), is expressed in T-cell lymphomas. J Pathol 2004; 202: 341–51.
    Direct Link:
  • 24
    Tsai WC, Chao YC, Lee WH, Chen A, Sheu LF, Jin JS. Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters. Histopathology 2006; 49: 388–95.
    Direct Link:
  • 25
    Zheng HC, Takahashi H, Murai Y, Cui ZG, Nomoto K, Miwa S, Tsuneyama K, Takano Y. Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis. Br J Cancer 2006; 95: 1371–8.
  • 26
    Ishibashi Y, Matsumoto T, Niwa M, Suzuki Y, Omura N, Hanyu N, Nakada K, Yanaga K, Yamada K, Ohkawa K, Kawakami M, Urashima M. CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer 2004; 101: 1994–2000.
    Direct Link:
  • 27
    Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis 2003; 20: 161–9.
  • 28
    Davidson B, Konstantinovsky S, Nielsen S, Dong HP, Berner A, Vyberg M, Reich R. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Clin Cancer Res 2004; 10: 7335–46.
View Full Article (HTML) Get PDF (519K)